PERSANO, MARA
 Distribuzione geografica
Continente #
EU - Europa 16.276
NA - Nord America 520
AS - Asia 206
AF - Africa 4
OC - Oceania 2
Totale 17.008
Nazione #
IT - Italia 16.091
US - Stati Uniti d'America 511
CN - Cina 109
SE - Svezia 87
SG - Singapore 40
IN - India 24
DE - Germania 19
NL - Olanda 18
GB - Regno Unito 16
FI - Finlandia 12
FR - Francia 11
CA - Canada 8
HK - Hong Kong 8
KR - Corea 7
IE - Irlanda 4
JP - Giappone 4
TH - Thailandia 4
VN - Vietnam 4
AT - Austria 3
BE - Belgio 3
ES - Italia 3
GR - Grecia 3
IR - Iran 3
AU - Australia 2
PL - Polonia 2
SC - Seychelles 2
BJ - Benin 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
IL - Israele 1
MO - Macao, regione amministrativa speciale della Cina 1
RO - Romania 1
RU - Federazione Russa 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
Totale 17.008
Città #
Cagliari 15.680
Uta 315
Boardman 102
Nyköping 77
Chandler 55
Fairfield 51
Ashburn 45
Houston 23
Rome 20
Singapore 20
New York 19
Pune 19
Seattle 19
Shanghai 18
Woodbridge 18
Cambridge 17
San Diego 15
Wilmington 15
Boston 14
Amsterdam 12
Guangzhou 12
Helsinki 12
Beijing 10
Los Angeles 10
Shenzhen 9
Toronto 8
London 7
Seoul 7
Paris 6
Zhengzhou 6
Hong Kong 5
Menlo Park 5
Dong Ket 4
Hefei 4
La Maddalena 4
Naples 4
Romainville 4
Jacksonville 3
Nakano 3
Peristeri 3
San Cipriano d'Aversa 3
Sassari 3
Turin 3
Vienna 3
Wuhan 3
Ann Arbor 2
Changzhou 2
Delhi 2
Don Mueang 2
Dublin 2
Enna 2
Florence 2
Gdansk 2
Godo 2
Islington 2
Jiaxing 2
Jinhua 2
Krefeld 2
Leuven 2
Livorno 2
Milan 2
Nanjing 2
Norwalk 2
Olbia 2
Pisa 2
Premià de Dalt 2
San Francisco 2
San Giorgio a Cremano 2
Sydney 2
Washington 2
Wuxi 2
Xian 2
Yantai 2
Abidjan 1
Alexandria 1
Amgaon 1
Ankara 1
Assèmini 1
Bergamo 1
Bilbao 1
Brno 1
Brussels 1
Chandigarh 1
Clifton 1
Cotonou 1
Dearborn 1
Dongyang 1
Ebisu 1
Exeter 1
Frattamaggiore 1
Gela 1
Hamburg 1
Heidelberg 1
Lecce 1
Mahé 1
Miami Beach 1
Moscow 1
Naaldwijk 1
New Bedfont 1
Port-of-spain 1
Totale 16.778
Nome #
Molecular-biology-driven treatment for metastatic colorectal cancer 2.551
New therapeutic targets in pancreatic cancer 1.460
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.350
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.180
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.041
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 787
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 756
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 754
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 749
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 727
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 672
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 609
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 558
Uncovering key targets of success for immunotherapy in pancreatic cancer 527
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 506
BRCA-mutant pancreatic ductal adenocarcinoma 432
Immune Checkpoint Inhibitors in the Treatment of HCC 420
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 383
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 333
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 273
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 212
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 202
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 116
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 111
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 92
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 57
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 56
null 47
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 46
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 39
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 34
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 32
Totale 17.112
Categoria #
all - tutte 24.860
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.860


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020126 0 0 0 0 0 0 55 16 12 10 8 25
2020/20212.423 32 51 33 869 469 283 94 163 63 161 109 96
2021/20221.411 84 65 4 47 57 107 68 164 112 154 244 305
2022/20233.508 301 460 353 253 266 336 167 261 246 394 310 161
2023/20243.526 145 134 122 196 301 612 613 263 195 212 348 385
2024/20256.118 2.461 2.961 696 0 0 0 0 0 0 0 0 0
Totale 17.112